Design Therapeutics, Inc. (NASDAQ:DSGN – Get Free Report) Director John P. Schmid purchased 17,809 shares of Design Therapeutics stock in a transaction dated Monday, March 25th. The shares were bought at an average price of $3.74 per share, with a total value of $66,605.66. Following the completion of the acquisition, the director now directly owns […]
Design Therapeutics, Inc. (NASDAQ:DSGN – Get Free Report) Director John P. Schmid acquired 9,156 shares of Design Therapeutics stock in a transaction on Friday, March 22nd. The stock was acquired at an average cost of $3.62 per share, for a total transaction of $33,144.72. Following the completion of the purchase, the director now owns 9,156 […]
Design Therapeutics, Inc. (NASDAQ:DSGN – Get Free Report) Director John P. Schmid bought 9,156 shares of the company’s stock in a transaction on Friday, March 22nd. The stock was purchased at an average cost of $3.62 per share, with a total value of $33,144.72. Following the completion of the transaction, the director now owns 9,156 […]
Design Therapeutics, Inc. (NASDAQ:DSGN – Get Free Report) has earned an average rating of “Hold” from the seven brokerages that are currently covering the stock, Marketbeat reports. Seven analysts have rated the stock with a hold rating. The average 1 year price target among brokerages that have issued a report on the stock in the […]
Design Therapeutics, Inc. (NASDAQ:DSGN – Get Free Report) has received an average recommendation of “Hold” from the seven research firms that are currently covering the company, MarketBeat.com reports. Seven equities research analysts have rated the stock with a hold rating. The average 1-year target price among brokers that have issued ratings on the stock in […]